Legend Biotech Corporation (NASDAQ:LEGN) has announced groundbreaking long-term data from its Phase 3 CARTITUDE-4 study, highlighting that a single infusion of CARVYKTI® (ciltacabtagene autoleucel) significantly boosted overall survival in patients with relapsed or lenalidomide-refractory multiple myeloma.
The data revealed a 45% reduction in the risk of death compared to standard therapies.
“These long-term results are groundbreaking and demonstrate that CARVYKTI significantly extends patients’ overall survival and meaningly improves their quality of life,” Maria-Victoria Mateos, M.D., Ph.D..
The results were presented at the International Myeloma Society Annual Meeting in Rio de Janeiro and align with Legend Biotech's pursuit of innovative cell therapies.
Following the announcement, Legend Biotech's share rose over 5% to $49.27.